Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Frederike Anne Straeten"'
Autor:
Mailin Hannah Marie Koecke, Jan‐Kolja Strecker, Frederike Anne Straeten, Carolin Beuker, Jens Minnerup, Antje Schmidt‐Pogoda
Publikováno v:
Brain and Behavior, Vol 14, Iss 3, Pp n/a-n/a (2024)
Abstract Aims To distinguish between the genuine cellular impact of the ischemic cascade by leukocytes and unspecific effects of edema and humoral components, two knock‐in mouse lines were utilized. Mouse lines Y731F and Y685F possess point mutatio
Externí odkaz:
https://doaj.org/article/34c106f181b74174bf5453a29971335d
Autor:
Steffen Pfeuffer, Thomas Müntefering, Leoni Rolfes, Frederike Anne Straeten, Susann Eichler, Joel Gruchot, Vera Dobelmann, Tim Prozorovski, Boris Görg, Mihael Vucur, Carsten Berndt, Patrick Küry, Tobias Ruck, Stefan Bittner, Dominik Bettenworth, Thomas Budde, Tom Lüdde, Sven G. Meuth
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 14, Iss 6, Pp 1199-1211 (2022)
Background & Aims: The 2-pore potassium channel subfamily K member 9 (KCNK9) regulates intracellular calcium concentration and thus modulates cell survival and inflammatory signaling pathways. It also was recognized as a risk allele for inflammatory
Externí odkaz:
https://doaj.org/article/66d58bba624540439c1c629a7cb0c453
Autor:
Steffen Pfeuffer, Thomas Müntefering, Leoni Rolfes, Frederike Anne Straeten, Susann Eichler, Joel Gruchot, Vera Dobelmann, Tim Prozorovski, Boris Görg, Mihael Vucur, Carsten Berndt, Patrick Küry, Tobias Ruck, Stefan Bittner, Dominik Bettenworth, Thomas Budde, Tom Lüdde, Sven G. Meuth
Publikováno v:
Cellular and molecular gastroenterology and hepatology. 14(6)
The 2-pore potassium channel subfamily K member 9 (KCNK9) regulates intracellular calcium concentration and thus modulates cell survival and inflammatory signaling pathways. It also was recognized as a risk allele for inflammatory bowel disease. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81851d0a5d1fa17901c53daa8ae01a9c
https://pubmed.ncbi.nlm.nih.gov/35973573
https://pubmed.ncbi.nlm.nih.gov/35973573
Autor:
Christoph Aufenberg, Sebastian Doerck, Michael Lang, Susanne Windhagen, Christoph Kleinschnitz, B. Tackenberg, Marinus Wieshuber, Sven G. Meuth, Refik Pul, Heinz Wiendl, Tobias Ruck, Rene Schmidt, Vera Straeten, Frederike Anne Straeten, Steffen Pfeuffer, Ralf A. Linker, Christian Eienbroeker, Jürgen Haas, De-Hyung Lee, Volker Limmroth, Luisa Klotz, Brigitte Wildemann, Marc Pawlitzki
Publikováno v:
Journal of neurology. 266(1)
Natalizumab (NTZ) was the first approved monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite proven and sustained efficacy, its use is limited by the risk of progressive multifocal leukoencephalopathy (PML)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48107ff6637fce885b34586735d6ba0
https://pubmed.ncbi.nlm.nih.gov/30446966
https://pubmed.ncbi.nlm.nih.gov/30446966